Dr. Reddy's Laboratories has successfully completed the Phase 1 study of its proposed biosimilar of Tocilizumab to be used in the treatment of rheumatoid arthritis in adults. The company's Tocilizumab biosimilar candidate 'DRL_TC' successfully met its primary and secondary endpoints in a Phase 1 study.
This Phase I study used a subcutaneous formulation to evaluate the pharmacokinetic equivalence, safety and immunogenicity of the company's Tocilizumab biosimilar candidate in comparison to reference products. The successful outcome of this study represents an important milestone in Dr Reddy's commitment to making high-quality biosimilar products more accessible and affordable to healthcare providers and patients around the world. Dr Reddy's is developing the proposed Tocilizumab biosimilar as both subcutaneous and intravenous formulations.
Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.
